我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

冠状动脉支架术后不同抗凝药物的疗效观察(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2003年第1期
页码:
17-19
栏目:
临床研究
出版日期:
2003-01-01

文章信息/Info

Title:
The effects of different anticoagulators after PTCA and coronary stent
作者:
贾国良; 郭文怡; 李伟杰; 李成祥; 栾荣华; 吕安林; 王小燕
第四军医大学西京医院心血管内科,陕西 西安710032
Author(s):
JIA Guo-liang; GUO Wen-yi; LI Wei-jie; LI Cheng-xiang; LUAN Rong-hua; Lǔ An-lin; WANG Xiao-yan
Department of Cardiology,Xijing Hospital,Fourth Military Medical University,Xi'an,Shaanxi 710032,China
关键词:
冠状动脉成形术; 支架; 抗凝药物
Keywords:
coronary angioplasty; stent; anticoagulato
分类号:
R318.1
DOI:
-
文献标识码:
A
摘要:
目的:观察经皮腔内冠状动脉成形术(PTCA)+支架置入术后不同抗凝药物对各种心脏事件发生的影响以及其副作用。方法:对884例冠心病患者置入1232个支架,在6～12月的短期随访中,观察术后不同抗凝药物和抗血小板药物对PTCA+支架术后各种心脏事件发生的影响以及其副作用。结果:在PTCA+支架术后,抗凝药物可使各种心脏事件发生率有显著降低,使用阿斯匹林+噻氯匹定及低分子肝素后未发生严重出血并发症及支架内血栓。结论:PTCA+支架术后使用不同抗凝药物和抗血小板药物效果没有明显差异。
Abstract:
AIM: To investigate the cardiac events and the side-effects of different anticoagulators after coronary stent.METHODS:1232 stents of 884 cases,followed up short-stage(6～12mo),to investigate the cardiac events and the side-effects of different anticoagulators after coronary stent.RESULTS:The morbility of cardiac events after PTCA and stent in patients using anticoagulators were singnificant reduced;No more hemorrhage and thrombus in stent in patients using Aspirin+ticlopidine+low molecular weight heparin (LMWH).CONCLUSION:It's no distinct differences in different anticoagulators after PTCA+stent.

参考文献/References

[1] Schomig A, Neumann FJ, Knotrati A, et al. A randomized comparison of antiplatelet and antlicoagulant therapy after placement of coronary stents [J] . N Engl Med, 1996, 334:1084-1089.

[2] Reffelmann T, Vom Dahl J, Hendriks F, et al. Reduction of inhospital complications after selective percutaneous transluminal coronary angioplasty using a combined pretreatment with ticlopidine and aspirin [J] . Z Kardiol, 1998, 87:872-880.

[3] 郑鹏翔, 华尔铨, 何祚佑, 等. 阿司匹林、噻氯匹啶、肝素预防冠状动脉支架亚急性血栓形成的效果 [J] . 中国介入心脏病学杂志, 1999, 7:124-125.

[4] Leon MB, Baim DS, Popma JJ, et al. A clinical trail comparing three antithrombotic drug regimens after coronary-artery stenting [J] . N Engl J Med, 1998,3:1665-1671.

[5] Carrozza JP, Baim DS, Charles A. Thrombotic and hemorrhagic complications of stenting coronary arteries:incidence, management and prevention [J]. Thromb Thrombolysis, 1995, 1:289-297.

[6] 高润霖, 陈纪林, 杨跃进, 等. 冠状动脉内支架置入术1000例-单中心经验分析 [J] . 中国循环杂志, 1999, 14(suppl):1-3.

[7] Grubegr L, Dangas G, Leon MB. Coronary artery stents:appropriate use of adjunctive pharmacotherapy to preventstent thrombosis [J] . Drugs Aging, 1999, 15:314-318.

[8] Dangas G, Colombo A. Platelet glycoprotein Ⅱ b/Ⅲ a antagonists in percutaneous coronary revascularization [J] . Am Heart J, 1999, 138(1Pt2):S16-23.

[9] Zidar JP. Low-molecular-weight heparins in coronary stenting(the ENTICES Trail). Enoxaparin and Ticlopidine after elective stenting[J].Am J Cardiol, 1998,19:1130-1131.

备注/Memo

备注/Memo:
收稿日期：2001-10-23.
更新日期/Last Update: 2003-01-01